Rosa Roselló

Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients

F. Ortíz-Sanjuán, Ricardo Blanco, V. Calvo-Río et al. · Arthritis & Rheumatology · 2014 · 143 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +10

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

I. García‐Doval, Beatriz Pérez-Zafrilla, M.Á. Descalzo et al. · Annals of the Rheumatic Diseases · 2010 · 108 citations · Full text

Veterinary Medicine, Clinical Sciences, Infectious Diseases +15

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study

Juan J. Gómez‐Reino, José Ramón Maneiro, Jorge Rodríguez Ruiz et al. · Annals of the Rheumatic Diseases · 2012 · 79 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Integration in microalgal bioprocess development: Design of efficient, sustainable, and economic processes

Mark Fresewinkel, Rosa Roselló, Christian Wilhelm et al. · Engineering in Life Sciences · 2014 · 42 citations · Full text

Life Sciences, Bioengineering, Biotechnology +17

VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist

Vicenç Torrente-Segarra, Asunción Acosta Pereira, Rosa Morlà et al. · Reumatología Clínica (English Edition) · 2016 · 13 citations

Pharmacy, Immunology, Pharmacotherapy +15